Virtual Investor is a leading platform providing investors with direct access to innovative companies, management teams and thought leaders.

Covered Companies

Series

What This Means

May 28, 2026

Abizer Gaslightwala, President and CEO of Akari Therapeutics highlights the significance of Akari’s first ASCO abstract acceptance and discussed newly presented preclinical data demonstrating combination synergy between Akari’s differentiated spliceosome-modulating ADC platform and a KRAS inhibitor in KRAS-mutated pancreatic cancer models.

CEO Connect

Featuring CNS Pharmaceuticals
May 20, 2026

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company’s recent $22.5 million financing, including its strategic pivot, progress made to date and how the capital positions CNS to identify and advance new assets aimed at driving long-term shareholder value.

KOL Connect

Featuring Ernexa Therapeutics
May 20, 2026

Dr. Elena Ratner, Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine and a member of Ernexa’s Board of Directors, discusses the evolving ovarian cancer treatment landscape and shares her perspective on Ernexa’s differentiated biological approach to addressing immunologically “cold” tumors.

KOL Connect

Featuring AIM Immuno
May 14, 2026

Professor Doctor Casper H.J. van Eijck, MD, PhD, Professor and Pancreato-biliary Surgeon at Erasmus Medical Center (“Erasmus MC”) and a consultant for AIM, and AIM Chief Executive Officer Thomas K. Equels, MS, JD, participate in a Virtual Investor KOL Connect segment.

Prof. Dr. van Eijck, a globally recognized pancreatic cancer clinical expert and the foremost expert in the use of Ampligen in pancreatic cancer, examines Ampligen’s mechanism of action, its potential to provide a positive immunotherapeutic approach, existing clinical data, development strategy, and anticipated regulatory milestones, supporting AIM’s focused commitment to advancing a potential new treatment option for patients with late-stage pancreatic cancer.

What This Means

Featuring enVVeno Medical
May 12, 2026

Robert Berman, Chief Executive Officer of enVVeno Medical, discusses the Company’s recent news announcing the U.S. Food and Drug Administration’s (FDA) first-ever IDE approval awarded to enVVeno to proceed with a U.S. pivotal study of a non-surgical replacement venous valve.

KOL Connect

Featuring Ernexa Therapeutics
May 11, 2026

Dr. Robert Pierce, Chief Scientific Office for Ernexa, provides insight into the complexities of ovarian cancer, highlights the patient journey from diagnosis through treatment, and emphasizes the persistent unmet need for more effective and durable treatment options.

Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company’s lead product candidate, ERNA101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.

What This Means

Featuring Akari Therapeutics
April 9, 2026

Abizer Gaslightwala, CEO of Akari Therapeutics, discusses the Company’s strategic partnership with WuXi XDC and its implications for platform validation and development acceleration, highlighting accelerated IND timeline for AKTX-101 and positioning within the rapidly evolving ADC landscape.

What This Means

Featuring Daré Bioscience
March 12, 2026

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses the significance of the FDA’s IND clearance and how this milestone allows Daré to advance DARE-HPV into Phase 2 clinical development in alignment with Daré’s broader strategy to address unmet needs in women’s health.

What This Means

Featuring GRI Bio
February 17, 2026

Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI Bio, discussed important insights from the Company’s recently reported additional positive Phase 2a data in Idiopathic Pulmonary Fibrosis (IPF), including a series of compelling biomarker results that demonstrate improvements in key drivers of fibrosis and lung repair.

View All Series